n-Lorem
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
| Formation | January 8, 2020 |
|---|---|
| Headquarters | Carlsbad, California |
CEO | Stanley T. Crooke |
| Website | https://www.nlorem.org/ |
The n-Lorem Foundation is a non-profit organization based in Carlsbad, California, established to develop personalized medicines using antisense RNA in order to treat patients of rare diseases.[1][2]
History
[edit]The organization was founded by Stanley T. Crooke, former CEO of Ionis Pharmaceuticals and head of research at GlaxoSmithKline, in 2020.[3] The n-Lorem Foundation was established in January 2020 with the goal of taking advantage of the technology developed at Ionis to provide experimental treatments to patients suffering from rare genetic disorders. The kind of patients treated at n-Lorem are those with nano-rare diseases, a term used to describe a disease that affects 1-30 people worldwide.
Patients with extremely rare genetic disorders have numerous unique challenges to face when seeking treatment. First, traditional pathways for accessing treatment do not work for such rare diseases. In fact, there are no pathways in place for nano-rare disorders. Second, finding a diagnosis and determining the genetic cause are often significantly more time-consuming than the diagnosis of a patient with a common disease. Physicians look for patterns when diagnosing patients; it is difficult to diagnose a disease that is not in the literature. Third, developing a drug for a smaller patient population is often more expensive. Finally, nano-rare genetic disorders are often rapidly fatal.[4] The development of any drug for treating patients with nano-rare genetic disorders then, must be very efficient in time and price.
Antisense Oligonucleotides (ASOs) are designed to bind to RNA and modify proteins expression.[5] In 2022, n-Lorem teamed up with Columbia University to create Silence ALS, an initiative to develop personalized experimental therapies to treat patients with rare-genetic forms of ALS.[6]
Mission
[edit]To bring experimental antisense oligonucleotide (ASO) therapies to patients with extremely rare diseases for free, for life.
References
[edit]- ^ Wosen, Jonathan (September 16, 2021). "A devastating rare disease. A medicine created just for her son. Will it work?". The San Diego Union-Tribune. Retrieved October 6, 2022.
- ^ Harold, Luker (December 7, 2020). "Local nonprofit helping patients with ultra-rare diseases". Del Mar Times. Retrieved October 6, 2022.
- ^ Whitlock, Jared (January 8, 2020). "With $4M in Funding, n-Lorem Foundation to Take on Rare Genetic Diseases". San Diego Business Journal. Retrieved October 6, 2022.
- ^ Crooke, Stanley T. (June 2021). "A call to arms against ultra-rare diseases". Nature Biotechnology. 39 (6): 671–677. doi:10.1038/s41587-021-00945-0. ISSN 1546-1696. PMID 34089038. S2CID 235346054.
- ^ Rinaldi, Carlo; Wood, Matthew J. A. (January 2018). "Antisense oligonucleotides: the next frontier for treatment of neurological disorders". Nature Reviews Neurology. 14 (1): 9–21. doi:10.1038/nrneurol.2017.148. ISSN 1759-4766. PMID 29192260. S2CID 28579577.
- ^ "New Initiative to Develop Personalized Therapies for People with Rare Genetic Forms of ALS". Columbia University Irving Medical Center. May 6, 2022. Retrieved October 6, 2022.
 | This article about a medical organization or association is a stub. You can help Wikipedia by expanding it. |